Section
Policy
Federal and state rules and laws that change what care costs or what prices must be disclosed: Medicare payment, price transparency, surprise billing, marketplace premiums and subsidies, Medicaid, and state laws on medical debt and facility fees.
-
Policy
Medicare drug plan premiums set to rise 50% for enrollees who stay put, KFF finds
The average premium for a stand-alone Medicare drug plan would climb from $34 to $51 a month in 2027 for people who keep their current plan, after federal regulators ended a subsidy that had held premiums down.
-
Policy
ACA open enrollment opens with benchmark premiums up 13% for 2027
Marketplace shoppers face a second straight year of double-digit premium increases, and a higher cap on what they can be asked to pay for care.
-
Policy
Judge strikes federal limit on Medicaid work rule exemption for medically frail adults
A federal court ruled that the administration narrowed a protection Congress wrote for people with serious health conditions, two months before Medicaid work requirements begin in expansion states.
-
Policy
Labor Department rule makes pharmacy benefit managers disclose pay to large employers
A Labor Department rule gives large self-insured employers a regular look at the rebates, fees and price spreads their drug benefit managers collect, starting with plan years that begin in mid-2027.
-
Policy
Medicare raises dialysis payments 2.7% for 2027, and patient coinsurance rises with it
A final rule sets next year's per-treatment rate for kidney dialysis, finishes folding phosphate binder drugs into the payment and expands extra pay for low-volume clinics.
-
Policy
Proposed rule would hold back ACA subsidies until eligibility is verified
A federal proposal would stop paying marketplace subsidies while eligibility questions are resolved, starting with 2028 coverage, and officials expect fewer people to enroll as a result.
-
Policy
Medicare proposal would cap costs for patients misled by wrong provider directories
A proposed rule carrying out a 2026 law would also limit how drug benefit managers are paid in Part D and end generic drug copays for the poorest enrollees in 2028.






